Acknowledgement
Supported by : National Research Foundation of Korea (NRF)
References
- Korean Liver Cancer Study Group and National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009;15:391-423. https://doi.org/10.3350/kjhep.2009.15.3.391
- Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009;44 Suppl 19:119-21. https://doi.org/10.1007/s00535-008-2244-z
- Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74. https://doi.org/10.1055/s-0030-1247133
- Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001;91:1479-86. https://doi.org/10.1002/1097-0142(20010415)91:8<1479::AID-CNCR1155>3.0.CO;2-0
- Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-40. https://doi.org/10.1002/hep.510300629
- Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 2010;78 Suppl 1:113-24. https://doi.org/10.1159/000315239
- Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Doseresponse relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002;54:150-5.
- Kim DY, Park W, Lim DH, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005;103:2419-26. https://doi.org/10.1002/cncr.21043
- Park W, Lim DH, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005;61:1143-50. https://doi.org/10.1016/j.ijrobp.2004.08.028
- Mornex F, Girard N, Beziat C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies: mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006;66:1152-8. https://doi.org/10.1016/j.ijrobp.2006.06.015
- Kim TH, Kim DY, Park JW, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with threedimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:225-31. https://doi.org/10.1016/j.ijrobp.2006.08.015
- Bae SH, Park HC, Lim DH, et al. Hypofractionated radiotherapy for small-sized hepatocellular carcinoma as salvage therapy: sustained local control and safety. J Korean Soc Ther Radiol Oncol 2010;28:85-90. https://doi.org/10.3857/jkstro.2010.28.2.85
- Bae SH, Park HC, Lim do H, et al. Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012;82:e603-7. https://doi.org/10.1016/j.ijrobp.2011.09.053
- Dawson LA. Overview: where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? Semin Radiat Oncol 2011;21:241-6. https://doi.org/10.1016/j.semradonc.2011.05.009
- Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology 2011;81 Suppl1:123-33. https://doi.org/10.1159/000333275
- Seong J, Park HC, Han KH, et al. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res 2003;27:30-5. https://doi.org/10.1016/S1386-6346(03)00162-1
- Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009;16:1587-96. https://doi.org/10.1245/s10434-009-0454-0
- Choi JH, Kim K, Chie EK, et al. Does adjuvant radiotherapy suppress liver regeneration after partial hepatectomy? Int J Radiat Oncol Biol Phys 2009;74:67-72. https://doi.org/10.1016/j.ijrobp.2008.06.1941
- Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995;31:1237-48. https://doi.org/10.1016/0360-3016(94)00418-K
- Liang SX, Huang XB, Zhu XD, et al. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child-Pugh Grade A cirrhosis. Radiother Oncol 2011;98:265-9. https://doi.org/10.1016/j.radonc.2010.10.014
- Dawson LA. Protons or photons for hepatocellular carcinoma? Let's move forward together. Int J Radiat Oncol Biol Phys 2009;74:661-3. https://doi.org/10.1016/j.ijrobp.2009.02.009
Cited by
- High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma vol.8, pp.None, 2012, https://doi.org/10.1186/1748-717x-8-250
- Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis vol.190, pp.9, 2014, https://doi.org/10.1007/s00066-014-0604-6
- Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma vol.190, pp.10, 2012, https://doi.org/10.1007/s00066-014-0643-z
- Fate of pulmonary nodules detected by computer-aided diagnosis and physician review on the computed tomography simulation images for hepatocellular carcinoma vol.32, pp.3, 2012, https://doi.org/10.3857/roj.2014.32.3.116
- Child-Pugh Score Maintenance in Cirrhotic Hepatocellular Carcinoma Patients after Radiotherapy: Aspects of Gastroduodenal Complications vol.100, pp.6, 2014, https://doi.org/10.1177/1778.19270
- Concurrent Chemoradiotherapy Shows Long-Term Survival after Conversion from Locally Advanced to Resectable Hepatocellular Carcinoma vol.55, pp.6, 2012, https://doi.org/10.3349/ymj.2014.55.6.1489
- Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma vol.47, pp.1, 2012, https://doi.org/10.4143/crt.2013.218
- Optimal follow-up duration for evaluating objective response to radiotherapy in patients with hepatocellular carcinoma: a retrospective study vol.34, pp.2, 2015, https://doi.org/10.5732/cjc.014.10136
- Dosimetric comparison of volumetric modulated arc therapy with robotic stereotactic radiation therapy in hepatocellular carcinoma vol.33, pp.3, 2012, https://doi.org/10.3857/roj.2015.33.3.233
- Normal liver sparing by proton beam therapy for hepatocellular carcinoma: Comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy vol.54, pp.10, 2012, https://doi.org/10.3109/0284186x.2015.1009637
- Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma vol.33, pp.4, 2015, https://doi.org/10.3857/roj.2015.33.4.276
- Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis vol.5, pp.11, 2016, https://doi.org/10.1002/cam4.893
- Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma vol.7, pp.26, 2012, https://doi.org/10.18632/oncotarget.9450
- A feasibility study evaluating the relationship between dose and focal liver reaction in stereotactic ablative radiotherapy for liver cancer based on intensity change of Gd-EOB-DTPA-enhanced magnetic vol.34, pp.1, 2012, https://doi.org/10.3857/roj.2016.34.1.64
- Defining Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma Patients Treated with Stereotactic Body Radiotherapy vol.8, pp.19, 2017, https://doi.org/10.7150/jca.21561